VeriMomIst palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine in der Schwangerschaft sicher?
No harmonised CLP classification or SCCS/CIR reproductive safety restriction was found for this ingredient. No peer‑reviewed reproductive or developmental toxicity data were identified. As a large palmitoyl‑peptide used topically, dermal absorption is expected to be negligible, and there is no structural or mechanistic evidence of reproductive toxicity. Sources consulted include PubChem, CosIng, PubMed (no reproductive studies), ECHA (no Annex VI harmonised classification), and EWG.
Pregnancy-safe products containing palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine
Related ingredients
Frequently asked questions
- Ist palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine in der Schwangerschaft sicher?
- No harmonised CLP classification or SCCS/CIR reproductive safety restriction was found for this ingredient. No peer‑reviewed reproductive or developmental toxicity data were identified. As a large palmitoyl‑peptide used topically, dermal absorption is expected to be negligible, and there is no structural or mechanistic evidence of reproductive toxicity. Sources consulted include PubChem, CosIng, PubMed (no reproductive studies), ECHA (no Annex VI harmonised classification), and EWG.
- Ist palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine während des Stillens sicher?
- No data indicating transfer into breast milk or lactation-related toxicity. Given the peptide's size/polarity and expected negligible systemic absorption after topical use, risk of exposure to breastfed infants is unlikely. No regulatory flags (ECHA Annex VI, SCCS, CIR) or peer‑reviewed evidence were found.
- Ist palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine sicher für Babyhaut?
- No infant‑specific reproductive or toxicology data located. Adult dermal absorption is expected negligible; however, infant skin has a higher surface‑area‑to‑weight ratio and immature barrier, so exposure score is increased by +1 for 0–3 yr. There is still no mechanistic or hazard evidence suggesting reproductive or developmental toxicity for infants.
- Wie bewertet VeriMom palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine?
- VeriMom bewertet palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine mit 100/100 (keine bekannten Risiken) basierend auf EU CosIng, ECHA-Klassifizierungen und PubMed-Studien.
- Was sind schwangerschaftssichere Alternativen zu palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine?
- Siehe unsere kuratierte Liste der schwangerschaftssicheren Alternativen zu palmitoyl dipeptide-5 diaminobutyroyl hydroxythreonine basierend auf ähnlicher Funktion.
Prüfe jede Zutatenliste in 2 Sekunden
Lade VeriMom kostenlos — scanne jedes Produkt und sieh sofort die Schwangerschafts-Sicherheitsbewertung.
Medizinischer Haftungsausschluss
Diese Informationen dienen ausschließlich Bildungszwecken und stellen keine medizinische Beratung dar. Sicherheitsbewertungen basieren auf öffentlich zugänglichen Daten und spiegeln möglicherweise nicht alle Risiken wider. Konsultieren Sie immer Ihren Arzt, bevor Sie ein Produkt während der Schwangerschaft oder Stillzeit verwenden.